Phase II Study of Docetaxel + Cetuximab + Concurrent Re-Irradiation (Intensity -Modulated Radiation Therapy, IMRT) for Patients With Locoregionally Recurrent Head and Neck Cancer.
Phase of Trial: Phase II
Latest Information Update: 29 Apr 2015
At a glance
- Drugs Cetuximab (Primary) ; Docetaxel (Primary)
- Indications Head and neck cancer
- Focus Therapeutic Use
- 01 Apr 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 29 Nov 2012 Planned end date changed from 1 Jul 2012 to 1 Jul 2013 as reported by ClinicalTrials.gov.
- 22 Nov 2011 Actual patient number is 14 according to ClinicalTrials.gov.